Diagnos Filed Regulatory Inquiry for CARA System

The company has initiated a formal request to clarify classification requirements for its diagnostic technology.

Updated on Sept. 28, 2026 in Asthma

Isometric editorial illustration of a sterile medical sensor module sitting on a laboratory workbench, representing regulatory classification procedures. — Diagnos filed a Section 513(g) inquiry with the U.S. Food and Drug Administration to clarify the regulatory classification of its CARA diagnostic system. AI Illustration. Upload story photo >

Live Poll

Should medical AI diagnostic systems undergo rigorous and standardized federal regulatory oversight?

Diagnos submitted a Section 513(g) Request for Information to the U.S. Food and Drug Administration regarding the CARA System. This filing serves to clarify the regulatory path for the technology following a previous pre-submission process.

Why it matters

This formal inquiry follows a specific recommendation from federal regulators, marking a step in establishing the regulatory status of the CARA system within the U.S. market. Clarifying these requirements is a standard procedure for medical device developers aiming to ensure compliance before further development.

Diagnos filed a Section 513(g) Request for Information to the U.S. Food and Drug Administration to determine classification and regulatory requirements for the CARA system. The action follows a prior Pre-Submission process conducted with the agency.

The players

Diagnos

A healthcare technology corporation based in Brossard, Quebec, focused on developing diagnostic screening systems.

U.S. Food and Drug Administration

The federal agency responsible for overseeing the safety, effectiveness, and classification of medical devices marketed in the United States.

The details

The Section 513(g) process allows manufacturers to request information from the FDA regarding the regulatory status of a device, including its classification and applicable requirements. By engaging in this formal step, the company seeks to address specific guidance provided by regulators during their previous discussions. This procedure is designed to provide clarity on how the device will be regulated before any future market access steps.

September 28, 2026: Diagnos submitted the formal Section 513(g) Request to the FDA.

Health Landscape

Medical device manufacturers regularly utilize the Section 513(g) process to align their development strategies with federal oversight standards. This step ensures that companies operating within the U.S. healthcare system have documented clarity on regulatory obligations.

This regulatory update reflects the ongoing development process for new diagnostic tools, though it does not yet change clinical care or the availability of the CARA system. Patients should consult their primary care physician regarding existing diagnostic standards for respiratory conditions.

The takeaway

The regulatory process ensures that new medical technologies undergo rigorous classification to meet safety and efficacy standards. Individuals can stay informed by tracking progress on new screening devices through official FDA advisory channels.